Sleep Apnea Implant Met Primary Clinical Endpoints
The Genio system demonstrated safety and efficacy in patients with complete concentric collapse of the soft palate.
Updated on Oct. 14, 2026 in Stroke
Live Poll
Should the FDA prioritize expedited approval for new medical devices targeting underserved patient populations?
The ACCCESS study has successfully met its primary safety and efficacy goals for the Genio hypoglossal nerve stimulation system. These findings could expand treatment options for patients with a specific type of airway collapse related to obstructive sleep apnea.
Why it matters
This study was conducted to support an expansion of the system's FDA indication to include patients with complete concentric collapse (CCC), a group that has historically been difficult to treat. If approved, this would provide a new surgical option for those whose airway structure prevents them from using standard therapies.
The ACCCESS study followed 47 patients over 12 months to measure the efficacy of the Genio hypoglossal nerve stimulation system. The trial reported an AHI responder rate of 77.2% and an ODI responder rate of 87.7%, with no device-related serious adverse events observed.
The players
Nyxoah
A medical technology company specializing in the development of neurostimulation therapies for obstructive sleep apnea.
The details
The Genio system works by delivering hypoglossal nerve stimulation, which helps prevent the tongue and soft palate from collapsing and obstructing the airway during sleep. This specific study focused on patients with complete concentric collapse of the soft palate, a condition where the entire airway narrows or closes significantly during breathing. By stimulating the nerve that controls tongue movement, the device helps keep the airway open.
Timeline
12 months post-implant: Responder rates and safety metrics were measured.
October 15-16, 2026: Results presentation at International Surgical Sleep Society meeting.
Health Landscape
The ACCCESS study provides a clinical benchmark that evaluates new hardware designs against existing hypoglossal nerve stimulation standards. This development marks a transition toward more anatomically specific interventions for sleep apnea, addressing complex airway configurations.
If you struggle with obstructive sleep apnea and have been told you have specific airway structural issues like complete concentric collapse, discuss whether emerging neurostimulation technologies might be appropriate for you. Determining if this device could be a future option requires a comprehensive evaluation by an otolaryngologist or sleep specialist.
The takeaway
The Genio system represents a promising development for treating complex obstructive sleep apnea, showing strong safety and efficacy in early trials. If you are currently managing sleep apnea, talk to your doctor about whether new nerve stimulation options could complement your existing care plan.
Further reading
For more information on the latest research in sleep-related health, visit the Stroke section.
Source note: This article includes information reported by Sleep Review.
Live Poll
Should the FDA prioritize expedited approval for new medical devices targeting underserved patient populations?
